Pyrazolopyrimidine compounds and their use in medicine

Abstract

Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical. n is 0 or 1. Q represents a radical of formula -(Alk1)p (X)r-(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a —O—, —S— or —NRA— link, wherein RA is hydrogen or C1-C6 alkyl; X represents —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —SO—, —C(═O)O—, —OC(═O)—, —C(═O)NRA—, —NR AC(═O)—, —C(═S)NRA, —NRAC(═S)—, —SO2NRA—, —NRASO2—, —OC(═O)NRA—, —NRAC(═O)O—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl. p, r and s are independently 0 or 1. R1 represents a radical -(Alk3)a-(Y)b-(Alk4)d-B wherein a, b and d are independently 0 or 1; Alk3 and Alk4 are optionally substituted divalent C,-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, —O—, —S—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is —NRA— and b is 1, then RA and the radical -(Alk4)d-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents hydrogen, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

Dependencies are inferred from the claim text.